



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------



RECEIVED

NOV 27 2002

TECH CENTER 1600/2900

EXAMINER

PAPER

13

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R., §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Regina M. DeBerry**, whose telephone number is (703) 305-6915. The examiner can normally be reached on **Mondays-Fridays 8:00 a.m.-4:30 p.m.**

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Gary Kunz** can be reached at (703)-308-4623. The fax number for the organization where this application or proceeding is assigned is (703)-308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Elizabeth C. Kemmerer

ELIZABETH KEMMERER
PRIMARY EXAMINER

Acknowledgment Receipt



SUBMISSION TYPE: BIO Sequence Filing

APPLICATION NUMBER: 09634363

FIRST NAMED INVENTOR: Kuanghui Lu

TITLE OF INVENTION: Methods and Reagents for Treating Glucose

Metabolic Disorders

ATTORNEY DOCKET NUMBER: CIBT-P02-058

FILE LISTING:

transmittal	tranCIBT-P02-058SequenceListing.xml 7067 Bytes
sequence-listing	CIBT-P02-058SequenceListing.txt 12130 Bytes
biotechnology-listing-filing	CIBT-P02-058SequenceListingbio.xml 957 Bytes
biotechnology-listing-filing	u-bio.dtd 3619 Bytes
biotechnology-listing-filing	e-bioseq.xsl 6067 Bytes

EFS ID: 19978

FILE SIZE: 17568 Bytes

TIMESTAMP: Mon Nov 18 14:19:44 EST 2002

MESSAGE DIGEST: kWstoRYART4oAb/AuS7buA==

DIGITAL CERTIFICATE HOLDER NAME: cn=David P. Halstead, ou=Registered Attorneys

UPLOAD STATUS: You have successfully uploaded your submission to USPTO

RECEIVED

NOV 27 2002

TECH CENTER 1600/2900



TRANSMITTAL FORM

Electronic Version 1.0.3

Application Number: 09/634,363

Stylesheet Version: 1.0

Attorney Docket CIBT-P02-
Number: 058

Submission Type: BIO

Sequence Filing

Methods and Reagents for Treating Glucose Metabolic Disorders

Assigned Examiner: Regina M. DeBerry

Group Art Unit 1647

First Named Inventor: Kuanghui Lu

RECEIVED

NOV 27 2002

SUBMITTED BY

Name: David P. Halstead

TECH CENTER 1600/2900

Registration Number: 44,735

Electronic Signature Mark: DYH Date Signed: 20021118

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

sequence-listing CIBT-P02-058SequenceListing.txt

biotechnology-listing-filing CIBT-P02-058SequenceListingbio.xml

I hereby certify that this correspondence is being transmitted to the Patent and Trademark Office on the following date. 2002-11-18

Name: David P. Halstead

Electronic Signature Mark: DYH

Comments: